Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ART of SABR: A Randomized Phase II Trial of Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer: Two Versus Five Fractions

NCT06325046 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT06325046
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06325046 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ART of SABR: A Randomized Phase II Trial of Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer: Two Versus Five Fractions
Lead sponsor
Mayo Clinic
Phase
Not applicable
Overall status
Recruiting
Start date
August 15, 2024
Completion date
April 30, 2032
Enrollment
164 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

localized prostate adenocarcinoma, stage i prostate cancer ajcc v8, stage ii prostate cancer ajcc v8, stage iii prostate cancer ajcc v8